<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                                                                                                 J. Med. Chem. 2010, 53, 6071&#226;&#8364;&#8220;6078 6071 <br />                                                                                                           DOI: 10.1021/jm1004754 <br />  <br />  <br />  <br />  <br /> Aryl Phosphoramidates 5-Phospho Erythronohydroxamic Acid, A New Class Potent <br /> Trypanocidal Compounds <br />  <br /> Gian Filippo Ruda,&#226;&#8364;&#160; Pui Ee Wong,&#226;&#8364;&#161; Vincent P. Alibu,&#226;&#8364;&#161; Suzanne Norval,&#226;&#8364;&#160; Kevin D. Read,&#226;&#8364;&#160; Michael P. Barrett,&#226;&#8364;&#161; and <br /> Ian H. Gilbert*,&#226;&#8364;&#160; <br /> &#226;&#8364;&#160; <br /> Division Biological Chemistry Drug Discovery, College Life Sciences, University Dundee, Sir James Black Centre, Dundee DD1 5EH, <br /> U.K., &#226;&#8364;&#161;Division Infection Immunity Wellcome Trust Centre Molecular Parasitology, Glasgow Biomedical Research Centre, <br /> University Glasgow G12 8TA, U.K. <br />  <br /> Received April 19, 2010 <br />  <br />             RNAi enzymatic studies shown importance 6-phosphogluconate dehydrogenase <br />             (6-PGDH) Trypanosoma brucei parasite <span id='am-3' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-4' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-5' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-6' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-8' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-9' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-14' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-16' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-17' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-18' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-21' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-22' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-25' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-26' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-27' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-29' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-30' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-31' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-34' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-36' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-37' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-38' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-39' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-40' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-41' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-42' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-44' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-45' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-46' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-48' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-49' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-52' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-53' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-58' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-60' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-61' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-63' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-65' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-72' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-73' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-76' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-78' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span>survival</span> make attractive drug target for <br />             development new treatments human African trypanosomiasis. 2,3-O-Isopropylidene- <br />             4-erythrono hydroxamate potent inhibitor parasite Trypanosoma brucei 6-phosphogluconate <br />             dehydrogenase (6-PGDH), enzyme pentose phosphate pathway. However, this <br />             compound does trypanocidal activity poor membrane permeability. Consequently, <br />             previously reported prodrug approach improve antiparasitic activity inhibitor by <br />             converting phosphate group charged phosphate prodrug. The activity prodrugs <br />             appeared dependent stability phosphate buffer. Here successfully further <br />             extended development aryl phosphoramidate prodrugs 2,3-O-isopropylidene-4-erythrono <br />             hydroxamate synthesizing small library phosphoramidates evaluating biological <br />             activity stability variety assays. Some compounds showed high trypanocidal activity <br />             good correlation activity stability fresh mouse blood. <br />  <br />  <br />  <br /> Introduction                                                             ference glycolysis. Inhibition 6-PGDH increase <br />                                                                          cellular level 6-phosphogluconate, potent inhibitor of <br />    Trypanosoma brucei parasite belonging order <br />                                                                          glycolysis. Moreover, reduce cellular pool of <br /> kinetoplastida. Two subspecies parasite, T. b. gam- <br />                                                                          NADPH, produced 6-PGDH glu- <br /> biense T. b. rhodesiense, responsible infection <br />                                                                          cose-6-phosphate dehydrogenase pentose phosphate <br /> called human African trypanosomiasis (HATa), one <br />                                                                          pathway. Diminished NADPH production reduce the <br /> of lethal neglected diseases developing world. <br />                                                                          parasite&#226;&#8364;&#8482;s ability withstand oxidative stress lower its <br /> Currently, drugs available treat HAT, of <br />                                                                          capability carry reductive biosyntheses. We dis- <br /> which developed 50 years ago (suramin, <br />                                                                          covered potent inhibitors 6-PGDH,3 typified by <br /> pentamidine, melarsoprol); fourth drug, eflornithine <br />                                                                          compound 1 (Figure 1), good selectivity the <br /> (D,L-R-difluoromethylornithine, DFMO) active only <br />                                                                          T. brucei enzyme mammalian orthologue. Unfortu- <br /> against T. b. gambiense,1 recently new combination, <br />                                                                          nately compounds phosphates not <br /> nifurtimox/eflornithine, introduced.2 However, <br />                                                                          readily enter cells. The lack bioavailability a <br /> these treatments far satisfactory issues <br />                                                                          general hindrance development phosphorylated enzyme <br /> that include toxicity, mode administration, efficacy <br />                                                                          inhibitors drugs inability molecules <span id='am-2' about='protege:TO' typeof='owl:Thing'>to</span> <br /> (suramin pentamidine active first <br />                                                                          cross cellular membranes reach desired site action/ <br /> stage disease). We interested developing <br />                                                                          target efficacious concentration.4 To circumvent this, <br /> new drugs treat HAT. <br />                                                                          phosphate-prodrugs developed. The design of <br />    We working inhibitors 6-phosphogluco- <br />                                                                          phosphate-prodrugs relatively new field5 been <br /> nate dehydrogenase (6-PGDH) potential way treat <br />                                                                          applied antivirals, anticancer, signaling regulators <br /> HAT. 6-PGDH involved step pentose <br />                                                                          research.6-10 A number phosphate-prodrugs recently <br /> phosphate pathway believed good drug target <br />                                                                          progressed clinical trials,11,12 proves applicability <br /> for chemotherapy HAT.3 The bloodstream form the <br />                                                                          approach. In previous work, reported the <br /> parasite relies exclusively glycolysis source energy; <br />                                                                          synthesis biological evaluation classes of <br /> therefore, parasite exquisitely sensitive inter- <br />                                                                          prodrug compound 1, compounds 2-613 (Figure 1). These <br />                                                                          prodrugs showed antiparasitic activity vitro cell <br />    *To correspondence addressed. Phone: &#195;&#190;44 1382          culture trypanosomes EC50 values micromolar <br /> 386 240. Fax: &#195;&#190;44 1382 386 373. E-mail: i.h.gilbert@dundee.ac.uk <br />                                                                        range. We investigated stability pseudophysiolo- <br />      Abbreviations: 6-PGDH, 6-phosphogluconate dehydrogenase; HAT, <br /> human African trypanosomiasis; PHLM, pooled human liver microsomal       gical conditions measuring half-life (phosphate buffer at <br /> assay.                                                                   pH 7.4 37 &#194;&#176;C). Yet despite good trypanocidal <br /> r 2010 American Chemical Society                                         Published Web 07/28/2010                      pubs.acs.org/jmc <br />  6072 Journal Medicinal Chemistry, 2010, Vol. 53, No. 16                                                                Ruda et al. <br />  <br />  <br />  <br />  <br /> Figure 1. Lead compound 1 corresponding phosphate prodrugs synthesized. <br />  <br />  <br />  <br />  <br /> Figure 2. Mechanism cleavage phosphoramidates proposed McGuigan et al.14 <br />  <br /> activity, phosphate masking groups showed low           rearranges, forming compound D. The final step is <br /> stability short half-life phosphate buffer,    proposed catalyzed &#226;&#8364;&#339;phosphoramidase&#226;&#8364;? enzyme <br /> exception aryl phosphoramidate 4,             produces final product E. The second pathway, which <br /> reasonable stability good activity. We took       predominant presence electron-withdrawing <br /> phosphoramidate 4 worked novel chemistry probe            groups phenyl ester, follows simple chemical hydro- <br /> stability phosphate buffer fresh blood         lysis release aromatic ester proceeds the <br /> hepatic microsomes related trypanocidal activity.       final product enzymatic cleavage amino acid group. <br />    Work McGuigan co-workers shown                Consequently, optimization chemical enzymatic <br /> possible optimize aryl phosphoramidate stability          stability aryl phosphoramidates achieved by <br /> combining variations amino acid chain, amino        alterations amino acid chain, amino acid ester, <br /> acid ester, aryl group. The proposed mechanism           substituent aryl ester group, illustrated in <br /> cleavage aryl phosphoramidate suggested Mcguigan             Figure 3. To increase stability prodrugs pursued <br /> et al.14 shown Figure 2. The cleavage follow main     following modifications: <br /> pathways. The route requires action carboxyl           &#226;&#8364;&#162; Increasing steric bulk amino acid chain <br /> esterase, hydrolyses amino acid ester form             (aimed reducing interaction esterases slow- <br /> free acid carboxylate (compound A). The oxygen                   ing formation intermediate A). <br /> carboxylate attacks phosphorus atom displaces            &#226;&#8364;&#162; Increasing steric bulk ester (aimed reducing <br /> the aryl ester form 5-membered intermediate B,               interaction esterases increasing chemical <br />  Article                                                                    Journal Medicinal Chemistry, 2010, Vol. 53, No. 16   6073 <br />  <br /> Scheme 1a <br />  <br />  <br />  <br />  <br />   a <br />       (a) DIAD, PPh3, N-hydroxyphthalimide, DCM; (b) Me-NHNH2, EtOH, reflux; (c) AlMe3, DCM. <br />  <br />                                                                       achieved clear, particularly specific activa- <br />                                                                       tion prodrug parasite, only <br />                                                                       minimal information relating metabolic capabilities of <br />                                                                       blood parasites. However, developing compounds <br />                                                                       conversion prodrug drug blood delayed <br />                                                                       improve prospects compounds entering the <br />                                                                       parasites achieving bioconversion target cell. <br />                                                                       Therefore focused efforts increasing stability of <br />                                                                       prodrugs blood assumption prodrug activation <br /> Figure 3. Planned modifications aryl-phosphoramidates.         occur parasites enhanced rate (Figure 4). <br />                                                                          To investigate stability prodrugs, compounds <br />      stability esters, slowing formation         incubated buffer pH 7.4 2.0 order to <br />      intermediate A).                                              investigate chemical hydrolysis, mouse blood to <br />    &#226;&#8364;&#162; Introduction electron donating groups phenyl           determine stability presence esterases. Finally of <br />      ring, aimed destabilizing anion generated          evaluated pooled human liver microsomal <br />      hydrolysis step, making aryl phenolate            assay (PHLM) determine metabolic stability. The data for <br />      poorer leaving group increasing stability        experiments shown Tables 1 2. The stability <br />      chemical hydrolysis. This slow conversion            data compared activity compounds against <br />      A B (mechanism 1) formation C (mechanism 2).         bloodstream form T. b. brucei BS427. <br />                                                                          Trypanocidal Activity Chemical Stability Phosphate <br /> Chemistry                                                             Buffer pH 7.4. Compounds assessed activity <br />                                                                       T. brucei. Most compounds showed submi- <br />    The phosphoramidates prepared according pre- <br />                                                                       cromolar EC50 values; compounds particularly <br /> viously reported methodology. The 2,4-dimethoxybenzyl <br />                                                                       potent: 15g, EC50 90 nM; 15l, EC50 40 nM; 15p, EC50 50 nM; <br /> erythrono hydroxamate obtained steps <span id='am-1' about='protege:FROM' typeof='owl:Thing'>from</span> <br />                                                                       15q, EC50 8 nM. <br /> 2,4-dimethoxy benzyl alcohol 2,3-O-isopropylidene ery- <br />                                                                          The chemical stability effects different substituents <br /> throno lactone (Scheme 1). The product 10 crystallized in <br />                                                                       analyzed comparing compounds are <br /> 40% yield EtOAc/hexane.13 <br />                                                                       stepwise changes. First, consider effect changing <br />    The phosphorochloridates 12a-e synthesized from <br />                                                                       aryl substituent. In general, electron donating groups <br /> the corresponding substituted phenols, phosphorus oxychloride <br />                                                                       increase buffer (chemical) stability compounds. In <br /> and corresponding amino acid ester hydrochloride <br />                                                                       analyzing comparing data compounds 15a (4- <br /> (Scheme 2). The phosphochloridates coupled with <br />                                                                       NO2), 15c (no substituent), 15h (4-Me), 15m (4-MeO), and <br /> the protected erythronohydroxamate 10 following conditions <br />                                                                       15o (2,3-diMe) (where amino acid moiety alanine <br /> developed McGuigan et al.7 The intermediates 14a-q were <br />                                                                       methyl ester), evident introduction electron- <br /> obtained moderate good yields. <br />                                                                       donating groups improves buffer stability pH 7.4 (half- <br />    The final step synthesis cleavage the <br />                                                                       life increases 0.85 h 15a 30 h compound <br /> protecting group hydroxamate moiety trifluoro- <br />                                                                       15o), translated, manner, higher <br /> acetic acid dichloromethane. The small library obtained <br />                                                                       vitro activity compound 15o (IC50 0.27 &#206;&#188;M) the <br /> in reasonable yields good purity mixtures diaste- <br />                                                                       active vitro alanine methyl ester series. There <br /> reoisomers chirality phosphorus atom. <br />                                                                       exceptions. The 4-methoxy derivative 15m de- <br />                                                                       monstrated increased buffer stability better in <br /> Biological Stability <br />                                                                       vitro activity compared analogue 15c. This data <br />    The prodrug approach treatment parasitic              follows similar trend McGuigan et al.,15 who <br /> disease HAT challenging complexity          reported 4-methoxyphenyl phosphoramidate of <br /> of (host &#195;&#190; parasite) particular requirements       nucleoside d4T slightly stable pH 7.4 the <br /> that prodrug fulfill order achieve desired         corresponding phenyl analogue. Also reason, com- <br /> effect. In case Trypanosoma brucei, ideal prodrug          pounds valine amino acid esterified an <br /> must good stability bloodstream mamma-           ethyl ester (15f) showed small decrease stability on <br /> lian host quickly converted active form        substituting phenyl ring 4-methyl (15l) <br /> (drug) inside parasite (Figure 4). Once converted         2,3-dimethyl (15p) substitutents. 2,3-Dimethylphenyl es- <br /> the active form, charged compound able           ters 4-methylphenyl esters showed comparable activity <br /> diffuse parasite. Whether ideal situation        stability (see pairs 15l-15p 15h-15o), are <br />  6074 Journal Medicinal Chemistry, 2010, Vol. 53, No. 16                                                                       Ruda et al. <br />  <br /> Scheme 2a <br />  <br />  <br />  <br />  <br />    a <br />      (a) POCl3, TEA, Et2O; (b) amino acid ester hydrochloride, TEA, DCM, rt; (c) NMI, DCM, (2,4-dimethoxybenzyl)-O-erythronoydroxic alcohol; <br /> (d) TFA, DCM, rt 15 min. <br />  <br />  <br />  <br />  <br /> Figure 4. Schematic representation selective delivery prodrugs trypanosomes (MG: masking group). <br />  <br /> generally active corresponding phenyl, 4-metho-              The importance amino acid chain seen by <br /> xyphenyl 4-nitrophenylesters.                                        analyzing pairs 15c-15e, 15h-15j, 15i-15l, 15d-15f, <br />  Article                                                                              Journal Medicinal Chemistry, 2010, Vol. 53, No. 16    6075 <br />  <br /> Table 1. Biological Activity Stability Phosphoramidates <br />  <br />  <br />  <br />  <br /> compd           R1         R2        R3       t1/2 pH 7.4 h       t1/2 pH 2 h       t1/2 mouse blood (min)      PHLM (mL/min/g)         EC50 (&#206;&#188;M) <br />  15aa         4-NO2       Me        Me              0.85                                                                                  43.8 <br />  15b          H           H         Me                                                       &lt;15                                          11.4 <br />  15ca         H           Me        Me              5                                        &lt;15                                           6.95 <br />  15d          H           Me        Et             29                                        &lt;15                                           0.78 <br />  15e          H           i-Pr      Me             21                                         45                       &lt;0.5                0.36 <br />  15f          H           i-Pr      Et             61                                        120                       &lt;0.5                0.24 <br />  15g          H           i-Pr      t-Bu           68                28                      120                        5.0                0.09 <br />  15h          4-Me        Me        Me             30                                        &lt;15                                           0.31 <br />  15i          4-Me        Me        Et             34                                                                                      0.18 <br />  15j          4-Me        i-Pr      Me             45                28                                                                    0.15 <br />  15l          4-Me        i-Pr      Et             25                15                         45                     &lt;0.5                0.04 <br />  15m          4-OMe       Me        Me                                8.5                                              &lt;0.5                3.79 <br />  15n          4-OMe       i-Pr      Et                                                                                 &lt;0.5                0.11 <br />  15o          2,3-Me      Me        Me             30                                                                                      0.27 <br />  15p          2,3-Me      i-Pr      Et             48                10                       60                       &lt;0.5                0.05 <br />  15q          2,3-Me      i-Pr      t-Bu          &gt;24                                       &gt;480                       10                  0.008 <br />   a <br />       Compounds 15a 15c reported previously.13 <br />  <br /> Table 2. Biological Properties Most Potent Trypanocidal Compounds <br />  <br />  <br />  <br />  <br />                                             1                        15l                       15g                    15p                    15q <br /> EC50 (&#206;&#188;M)                                  &gt;330                      0.04                      0.09                   0.05                   0.008 <br /> T1/2 mouse blood (min)                                               45                        120                    60                     480 <br /> T1/2 ph 7.4 (h)                                                      25                        30                     48                     24 <br /> PHLM Cli mL/min/g                                                    &lt;0.5                      5.0                    &lt;0.5                   10 <br /> clogD                                                                2.4                       2.6                    2.9                    3.6 <br />  <br /> and phenyl esters 15b, 15c, 15e. Changes                     15p (Et) 15q (t-Bu) (EC50 0.050 0.008 &#206;&#188;M, <br /> glycine alanine alanine valine increased buffer                    respectively). A relationship buffer stability pH <br /> stability case, exception 15i (Ala)-15l                    7.4 antiparasitic activity obvious, are <br /> (Val); case, compounds reasonably                        fewer data points. The tert-butyl esters similar half-lives <br /> comparable buffer stability half-lives 34 25 h,                     ethyl analogues (see pair 15p (Et) 15q (t-Bu) and <br /> respectively. The hindered amino acid glycine 15d                          pair 15f (Et) 15g (t-Bu)). Comparison ethyl esters <br /> showed lower buffer stability, difficult                     15d, 15i, 15l corresponding methyl ester analo- <br /> to measure half-life (data reported table). The                  gues 15c 15h 15j shows ethyl ester improves <br /> poor stability aryl phosphoramidate ob-                       trypanocidal activity buffer stability. <br /> served synthesis coupling phos-                         Overall, general correlation buffer stability <br /> phochoridate 13b erythronohydroxamate 10                               activity compounds, compounds showing <br /> produced prodrug 14b lowest yields                          longer half-life phosphate buffer active against <br /> (12%), degree decomposition occurred                           parasite (Figure 5). Thus moving compound 15a, <br /> during purification. With compounds,                       half-life 50 min, 15q, half- <br /> increase buffer stability corresponded increase                   life &gt;24 h, potency changes 44 0.008 &#206;&#188;M, an <br /> in activity parasites, valine better                increase activity 5000 times. The relationship <br /> alanine turn better glycine.                                   vitro antiparasitic data buffer stability almost <br />    The point variation amino acid ester                    certainly complicated presence esterases (see below) <br /> (R3). In terms antiparasitic activity, tert-butyl                    role removal ester. <br /> esters potent EC50 values ethyl                             We looked buffer (chemical) stability several <br /> methyl ester shown compounds 15e (Me), 15f (Et),                          compounds pH 2, compounds likely to <br /> and 15g (t-Bu) (EC50 0.36, 0.24, 0.09 &#206;&#188;M, respectively)                     survive stomach. The compounds showed small <br />  6076 Journal Medicinal Chemistry, 2010, Vol. 53, No. 16                                                                    Ruda et al. <br />  <br />                                                                       assayed good metabolic stability (&lt;0.5 mL/min/g). <br />                                                                       However, tert-butyl esters appeared susceptible <br />                                                                       metabolism. This extra liphophilicity of <br />                                                                       group. Liability tert-butyl derivatives hepatic <br />                                                                       metabolism mitigate utility drug candi- <br />                                                                       dates spite stability characteristics being <br />                                                                       favorable. <br />  <br />                                                                       Conclusions <br />                                                                          Compound 1 potent selective inhibitor T. brucei <br />                                                                       6-PGDH; however, inactive parasite, presum- <br />                                                                       ably presence phosphate group. By making <br />                                                                       prodrugs masking phosphate group, possi- <br />                                                                       ble prepare compounds activity the <br /> Figure 5. Correlation EC50 half-life prodrugs   parasite activity prodrugs appears correlate <br /> phosphate buffer pH 7.4.                                              buffer stability. In particular, aryl phosphorami- <br /> reduction (approximately 2-fold) stability acidic          date prodrugs appeared best balance stability <br /> conditions, preclude used                 activity. In article, optimization of <br /> orally.                                                               prodrugs evaluation. By variation ester, <br />    Mouse Blood Stability. The stability fresh mouse blood          R-amino substituent, substituent phenyl <br /> was investigated key compounds. This                ester phosphate prodrug, possible fine-tune <br /> indication stability esterases blood. Hydro-       buffer blood stability compounds. Thus, for <br /> lysis prodrug esterases probably key step       carboxylic ester, increasing bulk ester increases the <br /> conversion prodrugs active species (Figure 2).        buffer blood stability (presumably chemical esterase <br /> Many compounds showed short half-life,                  stability); R-amino substituent, increasing bulk also <br /> probably hydrolysis amino acid ester various         increases buffer blood stability. For phenyl <br /> esterases blood, leading loss masking groups.        substituent, electron-donating substituents increase buffer <br />    Looking series 15e-g 15p-q indicates            (chemical) stability revealing consistent effects on <br /> bulk ester increases, does blood stability. The order       blood stability. The prodrugs greatest buffer and <br /> of blood stability appears tert-butyl &gt; ethyl &gt; methyl.         blood stability tert-butyl ester, isopropyl <br /> We hypothesize order stability esters      substituent R-position, 2,3-dimethyl substituent <br /> to esterases. Similarly, increase bulk R-position        phenyl ring. By modifications, improved <br /> appears increase blood stability, seen            trypanocidal activity compounds 6.9 0.008 &#206;&#188;M <br /> comparison 15c (R2 = Me) 15e (R2 = i-Pr) 15d               stability mouse blood 15 min to <br /> (R2 = Me) 15f (R2 = i-Pr). Comparison 15c 15h              greater 480 min. <br /> and 15f, 15l, 15p indicates lack correlation           The biological data important chemical <br /> blood stability substituent phenyl ring. There-        stability phosphate buffer pH 7.4 vitro trypa- <br /> fore, compounds bulky esters R-substituents          nocidal activity compounds, possibly <br /> stable blood, presumably measure increased           assume Alamar Blue assay main decomposition <br /> stability esterases. However, substituent aromatic      pathway prodrugs assay media chemical <br /> ring smaller effect blood (esterase) stability.         hydrolysis. <br /> Again, consistent mechanism shown Figure 2.          Even proved mode action of <br />    It interesting compare experience              compounds inhibition enzyme 6-PGDH, <br /> reported literature prodrugs nucleotides.15,16      shown aryl phosphoramidate prodrugs derived <br /> In case nucleotide prodrugs, stability          inhibitor 1 higher antitrypanosomal activity <br /> prodrug moiety, human plasma, appears                compared parent compound. phosphoramidates show <br /> greater observed here. Possibly           correlation trypanocidal activity stability <br /> some intramolecular general acid/<span id='am-81' about='xsp:base' typeof='owl:Thing'>base</span> catalysis sys-           pseudophysiological conditions, EC50 values over <br /> tem causing rapid hydrolysis compounds. In              5000-fold lower compound 1. However, microsomal <br /> the case nucleotide prodrugs, different         (metabolic) instability observed tert-butyl-valinyl <br /> correlation substituents prodrugs anti-            phosphoramidates (15g 15q), indicating compounds <br /> viral activity compared seen here. According          probably susceptible hepatic clearance. <br /> to McGuigan co-workers, case phosphorami-                  This article shows possible improve com- <br /> dates d4T, higher esterase stability correlated        pounds optimizing prodrug moiety. Further optimiza- <br /> to higher potency compounds. The reported data                 tion require retaining good buffer blood (chemical <br /> showed t-butyl ester phosphoramidate d4T              esterase) stability prodrug moiety optimizing <br /> not degraded 21 h incubation presence              key developability properties molecule (such solubi- <br /> PLE.16 In case, however, t-butyl esters converted          lity metabolic stability). <br /> potent trypanocidal compounds reasonable time frame <br /> (2-8 h).                                                              Experimental Section <br />    Stability Pooled Human Liver Microsomes (PHLM).                   Parasite Testing. T. b. brucei (s427), wild-type cells were <br /> Compounds investigated metabolic stability,       cultured optimum density (1-2)   106 cells mL-1 in <br /> using human liver microsomes (Table 2). Most compounds                HMI-9 supplemented 10% fetal calf serum (FCS) under <br />  Article                                                                       Journal Medicinal Chemistry, 2010, Vol. 53, No. 16    6077 <br />  <br /> environmental conditions 37 &#194;&#176;C 5% CO2. Solutions               suspension left warm room temperature stirred for <br /> test compounds prepared culture media stock con-              12 h. The triethylamine salt filtered off, filtrate was <br /> centration 200 &#206;&#188;M diluted serially (1:2)               concentrated reduced pressure oil, used <br /> 96-well, flat-bottom solid white plates total 11 decreas-   step purification. <br /> ing concentrations (100 &#206;&#188;L well-1). The series            General Procedure B: Synthesis Phosphorochloridates. The <br /> was left blank, i.e., &#226;&#8364;&#339;drug-free&#226;&#8364;? (negative control). Cells         appropriate phosphorodichloridate (1.2 mol) amino <br /> prepared concentration 4   104 cells mL-1 added         acid esters hydrochloride (1 mol) stirred dry DCM with <br /> each respective compound series (100 &#206;&#188;L well-1). Plates           -78 &#194;&#176;C. TEA added dropwise syringe. The mixture <br /> were incubated 37 &#194;&#176;C/5% CO2 48 h prior addition         stirred 15 min -78 &#194;&#176;C warmed room <br /> Alamar Blue solution (20 &#206;&#188;L well-1, 0.49 mM 1X PBS, pH                temperature. The reaction monitored 31P NMR, and <br /> 7.4) followed 24 h incubation. Assay end points             analysis showed completed disappearance the <br /> were measured fluorimetrically fluorescence spectro-            starting material, reaction concentrated reduced <br /> meter (FluoStar, BMG LabTech, Germany) Optima pro-                   pressure. The residue taken Et2O, precipitated <br /> gram set &#206;&#187;excitation 544 nm &#206;&#187;emission 590 nm. Data      triethylamine salt filtered off. The filtrate concentrated <br /> analyzed using Prism 5.0 software obtain EC50 values. Exp-            vacuo used step purification. <br /> eriment performed duplicate repeated times.                General Procedure C: Synthesis Phosphoramidates. The <br />    Microsomal Stability. Each test compound (0.5 &#206;&#188;M) incu-           protected (2,4dimethoxybenzyl)erythrono hydroxamate (1 mol) <br /> bated pooled human liver microsomes (Tebu-Bio, UK;                  stirred appropriate phosphorochloridate phos- <br /> 0.5 mg/mL 50 mM potassium phosphate buffer, pH7.4)               phoramidate (1.2-2.1 mol) DCM (10 mol) cooled to <br /> reaction started addition excess NADPH (8 mg/mL                  -78 &#194;&#176;C argon atmosphere. N-Methyl imidazole (4 mol) <br /> 50 mM potassium phosphate buffer, pH7.4). Immediately,                added dropwise syringe solution. The mixture <br /> time zero, 3, 6, 9, 15, 30 min, aliquot (50 &#206;&#188;L)    stirred 15 min -78 &#194;&#176;C left warm room <br /> incubation mixture removed mixed acetonitrile               temperature stirred 4-12 h. The reaction monitored <br /> (100 &#206;&#188;L) stop reaction. Internal standard added        31P NMR quenched MeOH (1 mL). The organic <br /> samples, samples centrifuged sediment precipitated pro-           phase washed 0.5 M HCl (3   10 mL), dried over <br /> tein, plates sealed prior UPLCMSMS                  MgSO4, concentrated reduced pressure. The crude oil <br /> analysis using Quattro Premier XE (Waters).                            purified column chromatography 100% chloroform f <br />    XLfit (IDBS, UK) used calculate exponential                4% MeOH/chloroform. <br /> decay consequently rate constant (k) ratio              General Procedure D: Cleavage 2,4-Dimethoxybenzyl <br /> peak area test compound internal standard time             Group TFA. The protected hydroxamate stirred in <br /> point. The rate intrinsic clearance (CLi) compound            DCM room temperature, 2% TFA added syringe. <br /> was calculated using following calculation:                     The reaction stirred room temperature complete <br />  CLi &#195;&#176;mL=min=g liver&#195;&#382; &#194;&#188; k   V   microsomal protein yield                 disappearance starting material observed TLC <br />                                                                          (5% MeOH/DCM) 15-20 min. The white suspension diluted <br /> where V (mL/mg protein) incubation volume/mg protein              Et2O, white precipitate filtered off. The filtrate <br /> added microsomal protein yield taken 52.5 mg protein/g         concentrated reduced pressure purified chro- <br /> liver                                                                    matography eluting silica 100% DCM f 4% MeOH/ <br />    Verapamil used positive control confirm accep-            DCM. <br /> table assay performance.                                                    Examples final compounds given below. Details <br />     General Methods. 1H NMR, 13C NMR, 31P NMR, 2D-                   remainder compounds Supporting <br /> NMR spectra recorded Bruker Avance DPX                  Information. <br /> 300 spectrometer Bruker Avance DPX 500 spectrometer.                2,3-O-Isopropylidene Erythronocarboxamide-4-[phenyl(meth- <br /> Chemical shifts (&#206;&#180;) expressed ppm. Signal splitting               oxyglycinyl)phosphoramidate] (15b). The title compound was <br /> patterns described singlet (s), broad singlet (bs), doublet       synthesized following general procedure D compound <br /> (d), triplet (t), quartet (q), multiplet (m), combination thereof.    15b (41 mg, 0.07 mmol), TFA (40 &#206;&#188;L), DCM (5 mL). <br />    LCMS analyses performed Agilent HPLC 1100                Slightly orange hygroscopic foam, 22 mg (73%). 1NMR (500 <br /> (Waters XBridge Column) diode array detector series               MHz, CDCl3) &#206;&#180;: 1.27 (s, 3H, 1 C(CH3)2), 1.43 (d, 3H, J = 5.34 <br /> with Bruker MicroTof mass spectrometer. Compounds                 Hz, C(CH3)2), 3.64 (d, 3H, J = 4.70 Hz, OCH3), 3.68-3.80 (m, <br /> eluted using method A (methanol, methanol/water (95:5)            2H, NHCH2), 4.08-4.25 (m, 2H, CH2OP), 4.49-4.52 (m, 1H, <br /> or water/acetonitrile (1:1) &#195;&#190; 0.1% formic acid mobile             CHCH2OP), 4.66 (d, 1H, J = 7.47 Hz, C(O)CH), 7.06-7.09 (m, <br /> phase Phenomenex Gemini Column) method B                      1H, ArH), 7.12-7.14 (m, 2H, ArH), 7.21-7.25 (m, 2H, ArH). <br /> (water/acetonitrile 95:5 5:95 Water Xbridge column).             13 <br />                                                                             C NMR (125 MHz, CDCl3) &#206;&#180;: 24.50, 24.60 (C(CH3)2), 26.35, <br /> High-resolution electrospray measurements performed              26.67 (C(CH3)2), 42.80, 42.86 (NHCH2), 52.41, 52.46 (OCH3), <br /> Bruker MicroTof mass spectrometer.                                       65.04, 65.08, 65.24, 65.28 (CH2OP), 74.78, 75.27 (CHCH2OP), <br />    Thin layer chromatography (TLC) carried Merck              75.76, 75.84 (C(O)CH), 110.63, 110.64 (C(CH3)2), 120.16, <br /> silica gel 60 F254 plates using UV light and/or PMA KMnO4             120.20, 120.25 (ArCH), 125.02, 125.08 (ArCH), 129.69, 129.70 <br /> for visualization. TLC data given Rf value           (ArCH), 150.54, 150.60 (ArC-OP), 165.76, 165.17 (HNC(O)), <br /> corresponding eluent specified brackets. Column                171.44, 171.50, 171.60 (CO2Me). 31P NMR (121 MHz, CDCl3) <br /> chromatography performed using Fluka silica gel 60. All              &#206;&#180;: 3.68, 3.50. LCMS (ES&#195;&#190;): m/z 419.12 ([M &#195;&#190; H]&#195;&#190;, 100%); m/z <br /> reactions carried dry inert conditions (Ar            436.14 ([M &#195;&#190; NH4]&#195;&#190;, 20%). Rt 3.0 min, (purity &gt;99% UV). <br /> atmosphere) unless stated. Reactions using micro-              HRMS: Found 419.1223; C16H24N2O9P [M &#195;&#190; H&#195;&#190;] requires <br /> wave irradiation carried Biotage InitiatorTM micro-            419.1214. <br /> wave.                                                                       2,3-O-Isopropylidene Erythronocarboxamide-4-[phenyl(etho- <br />    The purity/identity compounds determined                  xyalaninyl) phosphoramidate] (15d). Compound 14d (200 mg, <br /> combination NMR (1H, 13C, 31P), LCMS, HRMS. The                   0.33 mmol) deprotected according general procedure <br /> purity compounds determined LCMS.                          D using TFA (89 &#206;&#188;L) DCM (9 mL). Orange foam, 93 mg <br />     General Procedure A: Synthesis Phosphorodichloridates. A          (62%). The compound contains traces TFA. 1H NMR (500 MHz, <br /> solution phosphorus oxychloride (1 mol) appropriate           CDCl3) &#206;&#180;: 1.16-1.28 (m, 9H, CH2CH3 &#195;&#190; CHCH3 &#195;&#190; 1 of <br /> phenol (1 mol) dry diethyl ether cooled -78 &#194;&#176;C,                C(CH3)2), 1.43, 1.42 (2s, 3H, 1 C(CH3), 3.86-4.04 (m, 2H, <br /> followed addition triethyl amine (1 mol). The white            CHCH3 &#195;&#190; OH), 4.09 (q, 2H, J = 6.9 Hz, OCH2CH3), 4.12-4.19 <br />  6078 Journal Medicinal Chemistry, 2010, Vol. 53, No. 16                                                                                     Ruda et al. <br />  <br /> (m, 2H, CH2OP), 4.32 (bs, 0.5H, PNH), 7.08 (q, 1H, J = 7.4 Hz,                       Torreele, E.; Kande, V. Nifurtimox-eflornithine combination <br /> ArH), 7.10-7.15 (m, 2H, ArH), 7.22-7.26 (m, 2H, ArH), 8.89,                          therapy second-stage African Trypanosoma brucei gambiense <br /> 9.20 (2bs, 1H, ONH). 13C NMR (125 MHz, CDCl3) &#206;&#180;: 14.07,                              trypanosomiasis: multicentre, randomised, phase III, non-infer- <br />                                                                                      iority trial. Lancet 2009, 374, 56&#226;&#8364;&#8220;64. <br /> 14.10 (CH2CH3), 20.82, 20.95 (CHCH3), 24.35, 24.52, 26.25,                     (3)   Dardonville, C.; Rinaldi, E.; Barrett, M. P.; Brun, R.; Gilbert, I. H.; <br /> 26.64 (C(CH3)2), 50.01, 50.29 (CHCH3), 61.82 (OCH2CH3),                              Hanau, S. Selective inhibition Trypanosoma brucei 6-phospho- <br /> 64.84 (CH2OP), 75.40, 75.75 (CHCH2OP), 75.84, 76.08 (C(O)-                           gluconate dehydrogenase high-energy intermediate transi- <br /> CHCH), 110.46, 110.54 (C(CH3)2), 120.15, 120.33, 120.37, (ArCH),                     tion-state analogues. J. Med. Chem. 2004, 47, 3427&#226;&#8364;&#8220;3437. <br /> 125.02, 125.08 (ArCH), 129.73 (ArCH), 150.49, 150.52 (ArC-                     (4)   Hecker, S. J.; Erion, M. D. Prodrugs phosphates phospho- <br /> OP), 165.12 (HNC(O)), 173.49, 173.72 (CO2Et). 31P NMR (121                           nates. J. Med. Chem. 2008, 51, 2328&#226;&#8364;&#8220;2345. <br />                                                                                (5)   Schultz, C. Prodrugs biologically active phosphate esters. <br /> MHz, CDCl3) &#206;&#180;: 2.56, 2.30. LCMS (ES&#195;&#190;): m/z 447.18 ([M &#195;&#190;                              Bioorg. Med. Chem. 2003, 11, 885&#226;&#8364;&#8220;898. <br /> H]&#195;&#190;, 100%). Rt 3.4 min, (purity 97.6% UV). HRMS: Found                         (6)   Jones, R. J.; Bischofberger, N. Minireview&#226;&#8364;&#8221;Nucleotide Prodrugs. <br /> 447.1532; C18H28N2O9P [M &#195;&#190; H&#195;&#190;] requires 447.1527.                                    Antivir. Res. 1995, 27, 1&#226;&#8364;&#8220;17. <br />    2,3-O-Isopropylidene Eerythronocarboxamide-4-[phenyl(meth-                  (7)   McGuigan, C.; Pathirana, R. N.; Balzarini, J.; Declercq, E. Intra- <br /> oxyvanlinyl)phosphoramidate] (15e). The title compound                           cellular Delivery Of Bioactive Azt Nucleotides By Aryl Phosphate <br /> synthesized following general procedure D 14e (191                          Derivatives Of Azt. J. Med. Chem. 1993, 36, 1048&#226;&#8364;&#8220;1052. <br />                                                                                (8)   Girardet, J. L.; Perigaud, C.; Aubertin, A. M.; Gosselin, G.; Kirn, <br /> mg, 0.31 mmol), TFA (40 &#206;&#188;L), CM (5 mL). Orange foam, 62                          A.; Imbach, J. L. Increase anti-HIV activity D4T human <br /> mg (43%). 1H NMR (500 MHz, CDCl3) &#206;&#180;: 0.76-0.85 (m, 6H,                               T-cell culture use sate pronucleotide approach. Bioorg. <br /> CH(CH3)2), 1.29-(d, 3H, J = 3.0 Hz, 1 C(CH3)2), 1.44 (s, 3H,                      Med. Chem. Lett. 1995, 5, 2981&#226;&#8364;&#8220;2984. <br /> 1 C(CH3)2), 1.95-2.02 (m, 1H, CH(CH3)2), 3.64 (d, 3H,                       (9)   Meier, C. 2-Nucleos-50 -O-yl-4H-1,3,2-benzodioxaphosphinin-2- <br /> J = 10.6 Hz, OCH3), 3.85-3.87 (m, 1H, NHCH), 3.85-3.87 (d,                           oxides&#226;&#8364;&#8221;a new concept lipophilic, potential prodrugs biolo- <br />                                                                                      gically active nucleoside monophosphates. Angew. Chem., Int. Ed. <br /> 1H, J = 11.2 Hz, PNH), 4.14 (t, 1H, J = 4.3 Hz, CHHOP),                              1996, 35, 70&#226;&#8364;&#8220;72. <br /> 4.18-4.35 (m, 1H, CHHOP), 4.49-4.53 (m, 1H, CHCH2OP),                         (10)   Farquhar, D.; Khan, S.; Srivastva, D. N.; Saunders, P. P. Synthesis <br /> 4.69 (dd, 1H, J1 = 3.0 Hz, J2 = 7.5 Hz, C(O)CHCH), 7.06-7.10                         And Antitumor Evaluation Of Bis[(Pivaloyloxy)Methyl] 20 - <br /> </body></html>